Curcumin as “Curecumin”: From kitchen to clinic
TLDR
Curcumin, a spice once relegated to the kitchen shelf, has moved into the clinic and may prove to be "Curecumin", a therapeutic agent in wound healing, diabetes, Alzheimer disease, Parkinson disease, cardiovascular disease, pulmonary disease, and arthritis.About:
This article is published in Biochemical Pharmacology.The article was published on 2008-02-15 and is currently open access. It has received 1897 citations till now. The article focuses on the topics: Curcumin & Inflammatory bowel disease.read more
Citations
More filters
Journal ArticleDOI
Bioavailability of curcumin: problems and promises.
TL;DR: Enhanced bioavailability of curcumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for treatment of human disease.
Journal ArticleDOI
Curcumin: From ancient medicine to current clinical trials
TL;DR: Curcumin exhibits great promise as a therapeutic agent, and is currently in human clinical trials for a variety of conditions, including multiple myeloma, pancreatic cancer, myelodysplastic syndromes, colon cancer, psoriasis and Alzheimer’s disease.
Journal ArticleDOI
Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases
TL;DR: Evidence for the potential role of curcumin in the prevention and treatment of various proinflammatory chronic diseases is provided and its features, combined with the pharmacological safety and negligible cost, renderCurcumin an attractive agent to explore further.
Journal ArticleDOI
The Essential Medicinal Chemistry of Curcumin
Kathryn M. Nelson,Jayme L. Dahlin,Jonathan Bisson,James G. Graham,Guido F. Pauli,Michael A. Walters +5 more
TL;DR: Evidence is provided that curcumin is an unstable, reactive, nonbioavailable compound and, therefore, a highly improbable lead and, on the basis of this in-depth evaluation, potential new directions for research onCurcuminoids are discussed.
Journal ArticleDOI
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature.
Preetha Anand,Sherin G. Thomas,Ajaikumar B. Kunnumakkara,Chitra Sundaram,Kuzhuvelil B. Harikumar,Bokyung Sung,Sheeja T. Tharakan,Krishna Misra,Indira K. Priyadarsini,Kallikat N. Rajasekharan,Bharat B. Aggarwal +10 more
TL;DR: This review focuses on the status of all these approaches in generating a "super curcumin," a homodimer of feruloylmethane containing a methoxy group and a hydroxyl group, a heptadiene with two Michael acceptors, and an alpha,beta-diketone.
References
More filters
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003 and is able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame.
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Period 1981−2002
TL;DR: From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.
Journal Article
Anticancer potential of curcumin: preclinical and clinical studies.
TL;DR: Evidence has also been presented to suggest that curcumin can suppress tumor initiation, promotion and metastasis, and Pharmacologically,Curcumin has been found to be safe.
Journal ArticleDOI
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Fusheng Yang,Giselle P. Lim,Giselle P. Lim,Aynun N. Begum,Aynun N. Begum,Oliver J. Ubeda,Oliver J. Ubeda,Mychica Simmons,Mychica Simmons,Surendra S. Ambegaokar,Surendra S. Ambegaokar,Pingping P. Chen,Pingping P. Chen,Rakez Kayed,Charles G. Glabe,Sally A. Frautschy,Sally A. Frautschy,Gregory M. Cole,Gregory M. Cole +18 more
TL;DR: It is suggested that low dose curcumin effectively disaggregates Aβ as well as prevents fibril and oligomer formation, supporting the rationale forCurcumin use in clinical trials preventing or treating AD.
Journal Article
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Ann-Lii Cheng,Hsu Ch,Lin Jk,Hsu Mm,Yunn-Fang Ho,Shen Ts,Ko Jy,Lin Jt,Bor-Ru Lin,Ming-Shiang W,Yu Hs,Shiou-Hwa Jee,Chen Gs,Chen Tm,Chi-An Chen,Lai Mk,Yeong-Shiau Pu,Min-Hsiung Pan,Wang Yj,Tsai Cc,Hsieh Cy +20 more
TL;DR: It is demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months and a biologic effect ofCurcumin in the chemoprevention of cancer is suggested.